DRRX250117C2000
- 0.05
- 0.000.00%
Durect Newsroom
Oppenheimer Remains a Buy on Durect (DRRX)
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
Express News | DURECT Corp - Transaction Extends DURECT Cash Runway Through First Half of 2025
Express News | DURECT Corporation Announces Sale of Alzet® Product Line to Lafayette Instrument Co. for $17.5 Million
Branford Castle-Backed Lafayette Instrument Acquires Alzet Osmotic Pumps
US Manufacturing Index Rises To 43, Highest Since 2020
Durect | 10-Q: Q3 2024 Earnings Report
Northland Securities Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $8.5
Northland Securities Sticks to Its Buy Rating for Durect (DRRX)
Oppenheimer Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Durect(DRRX.US) With Hold Rating
H.C. Wainwright Remains a Hold on Durect (DRRX)
HC Wainwright & Co. Reiterates Neutral on Durect
DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript Summary
DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript
Earnings Flash (DRRX) DURECT CORPORATION Reports Q3 Revenue $1.9M
Durect | 8-K: DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
Durect: Q3 Earnings Snapshot
Durect: Seeking to Initiate Phase 3 Registrational Trial for Larsucosterol With Topline Results Expected Within Two Years of Initiation >DRRX